Top 300 Pharmacy Drug Cards


Class: Antiretroviral Agent, Integrase Inhibitor

Dosage Forms. Tablet: 200 mg; Chewable Tablet: 25 mg; 100 mg


Common FDA Label Indication, Dosing, and Titration.

1. Treatment of HIV-1 infection in combination with other antiretroviral agents: Adults and Children ≥12 y, 400 mg po bid; Children <12 years, weight based

Off-Label Uses. None

MOA. Raltegravir inhibits the catalytic activity of integrase HIV-1 integrase, thus preventing integration of the proviral gene into human DNA.

Drug Characteristics: Raltegravir


Medication Safety Issues: Raltegravir


Drug Interactions: Raltegravir


Adverse Reactions: Raltegravir


Efficacy Monitoring Parameters. HIV viral load, CD4 count, HIV resistance testing.

Toxicity Monitoring Parameters. Liver function tests, bilirubin, CBC, glucose.

Key Patient Counseling Points. Take with or without food. May chew or crush the chewable tablet. Does not prevent transmission of HIV; practice safe sex.

Clinical Pearls. Not recommended for children less than 2 y of age. Recommended as a first-line therapy with tenofovir/emtricitabine in antiretroviral naïve patients.

If you find an error or have any questions, please email us at Thank you!